Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | RAPGEF3 | O95398 | 4/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4209318 | 0.82 | TP53 (0.42) | RAPGEF3MAPTMAPK1 | |
| SCHEMBL1809204 | 0.80 | ALDH1A1 (0.50) | ALDH1A1RAPGEF3HPGDMAPK1 | |
| SCHEMBL1807534 | 0.78 | ALDH1A1 (0.43) | ALDH1A1PTPN1MAPTHPGDRECQL | |
| Hydrochloric Acid SCHEMBL9315107 | 0.78 | ALDH1A1 (0.49) | ALDH1A1RAPGEF3HPGDMAPK1 | |
| SCHEMBL24710097 | 0.77 | ALDH1A1 (0.42) | ALDH1A1RAPGEF3PTPN1MAPTHPGD | |
| SCHEMBL20320525 | 0.74 | HCAR2 (0.34) | ALDH1A1 | |
| SCHEMBL16245722 | 0.73 | MBOAT4 (0.30) | — | |
| SCHEMBL10044258 | 0.72 | HCRTR1 (0.39) | ALDH1A1RAPGEF3PTPN1MAPTHPGD | |
| SCHEMBL6371376 | 0.72 | ALDH1A1 (0.44) | ALDH1A1RAPGEF3PTPN1MAPTHPGD | |
| SCHEMBL19228450 | 0.71 | ALDH1A1 (0.49) | ALDH1A1PTPN1MAPTHPGDRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LCK | ALDH1A1 4650/4885RAPGEF3 849/4885PTPN1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.